Description: Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, and the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases. The company was incorporated in 2008 and is headquartered in Lund, Sweden.
Home Page: www.idogen.com
Medicon Village
Lund,
223 81
Sweden
Phone:
46 4 62 75 63 30
Officers
| Name | Title |
|---|---|
| Dr. Christina Herder Ph.D. | Acting CEO & Director |
| Prof. Leif G. Salford M.D., Ph.D. | Founder & Chairman of the Scientific Advisory Board |
| Mr. Ingvar Karlsson | Chief Financial Officer |
| Mr. Dennis B. Henriksen M.Sc., Ph.D. | Chief Technology Officer |
| Ms. Hanjing Xie | Chief Medical Officer |
| Mr. Rory Graham | Chief Regulatory Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8274 |
| Price-to-Sales TTM: | 3.7124 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |